1 / 11

Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku

Preclinical evaluation of safety, efficacy, immunogenicity of a recombinant rBCG Pasteur B vaccine. Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku. Pre-clinical study. Objective

tallulah-williamson
Download Presentation

Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preclinical evaluation of safety, efficacy, immunogenicity of a recombinant rBCG Pasteur B vaccine Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku

  2. Pre-clinical study • Objective • To assess the safety (Reactogenecity and toxicity) and tolerability of rBCG Pasteur B vaccine compared to BCG • To assess the immunogenicity of rBCG Pasteur B vaccine compared to BCG • To assess the protective efficacy of rBCG Pasteur B vaccine compared to BCG

  3. Vaccine • This rBCG, a substitute for BCG, is prophylactic vaccine is intended to be used at birth to prevent infection from Mycobacterium tuberculosis. • Source of the vaccine: PASTEUR B LAB • Vaccine composition: rBCG∆mbtB∆UreC:pfoA-85AB-PPE44-DA-1 • Vaccine reconstitution: • Vaccine dose: • 5x 105, 5x106 , 5x107cfu • Number of dose: 1 dose • Route of immunization: Subcutaneous (mice and guinea pig) and Intradermal (NHP

  4. 2. Animal studies

  5. Flow chart Vaccine (n=105/105/6) BCG (n=105/105/6) Mice, Guinea Pigs & NHP Low Medium High Dose Route of immunization Subcutaneous (mice and Guinea pig) Intradermal (NHP) • Safety (5/group) • General health • Body weight • Immunogenicity (5/group) • Luminex • Flow cytometry • Protection (5 /group) • Survival time • Pathology • Weight change • Bacterial burden TNF, IL-2, IFN-γ, IL-10, TGF-β, IL-10, IL-4

  6. 3. Safety and toxicity testing in Mice and Guinea pig rBCG Immunocompromised (SCID) mice (n=30) Sacrificed for pathological examination and check for clearance of the vaccine (spleen, lung & liver) BCG 1d 2wk 8wk 12wk 16 wk rBCG Immunocompetent Mice (n=30) BCG • follow • General health status • Weight loss • Hematology • Clinical chemistry • Histopathology rBCG Guinea pig (n=30) BCG

  7. 4. Immunogenicity studies in animal models (Mice and Guinea Pigs) 4 week Vaccine (n=15) vaccination BCG (n=15) Sacrifice mice and homogenate the spleen and collect cells • Parameters to be measured • IL-2, IFN-γ, TNF-α, IL-10, IL-4, IL-17 producing CD4 and CD8 T cells = Sacrifice time

  8. 4. Efficacy studies in animal models (Mice, Guinea Pigs and NHP) Mice &Guinea Pigs (n=120) 4 week n=5 12 week n=5 BCG (n=60) vaccine 4 week (challenge) 8 week n=5 24 week n=5 Vaccine (n=60) NHP= 6 vaccine 6 week (challenge) 24 week n=3 40 week n=3 • Parameters to be measured • Bacterial burden (lung, spleen, liver) • Histopathological examination of lung, spleen, and liver • Body weight = Sacrifice time

  9. 5. Recommendation/ Expectedoutcomes • Safety profile of the new vaccine is excellent even in immunocompromised animals. • The vaccine would be very immunogenic and elicit protective Cell Mediated Immunity (CMI) polarized to Th1 type of response. • The new vaccine would enhance survival of Guinea pig infected with high dose of H37Rv with a marked reduction in bacterial load in different organs.

  10. Thank you for your attention!

More Related